论文部分内容阅读
目的观察阿莫西林克拉维酸钾干混悬剂对感染引起的新生儿高胆红素血症的治疗效果并进行成本分析。方法将2006年1月-2008年3月皖南医学院附属池州医院因感染所致新生儿高胆红素血症新生儿104例患儿随机分为观察组和对照组两组。观察组予口服阿莫西林克拉维酸钾干混悬剂抗感染治疗,而对照组予阿洛西林静脉点滴治疗,两组患儿均予蓝光光疗等综合退黄治疗措施。观察两组患儿治疗效果,采用最小成本分析法对两组进行评价。结果两组患儿在痊愈率、有效率、药物不良反应发生率、疗程及住院费用方面差异无统计学意义(P>0.05);观察组在药品费用、总成本及成本-效果比方面较对照组差异有统计学意义(P<0.01)。结论口服阿莫西林克拉维酸钾干混悬剂对感染引起的新生儿高胆红素血症相对于静脉应用阿莫西林具有明显的药物经济学优势。
Objective To observe the therapeutic effect of amoxicillin and clavulanate potassium dry suspension on neonatal hyperbilirubinemia caused by infection and carry out cost analysis. Methods A total of 104 neonates with neonatal hyperbilirubinemia due to infection were randomly divided into observation group and control group from January 2006 to March 2008 in Chizhou Hospital affiliated to Wannan Medical College. The observation group was treated with oral amoxicillin and clavulanate dry suspension, while the control group was treated with azlocillin intravenously, and the two groups were treated with blue light therapy and other methods. The therapeutic effects of the two groups were observed, and the two groups were evaluated by minimum cost analysis. Results There was no significant difference in cure rate, effective rate, incidence of ADR, course of treatment and hospitalization between the two groups (P> 0.05). Compared with the control group, the cost, total cost and cost-effectiveness The difference was statistically significant (P <0.01). Conclusion Oral administration of amoxicillin and potassium clavulanate dry suspension has significant pharmacoeconomical advantages over intravenous amoxicillin in neonates with hyperbilirubinemia due to infection.